(E/Z)-Eltrombopag-¹³C₄ 是 E-Eltrombopag 与 Z-Eltrombopag 异构体的混合物，带有 ¹³C 标记。Z-Eltrombopag 是一种具有口服活性的 thrombopoietin-receptor 非肽激动剂。Eltrombopag 可促血小板的活性，用于治疗血小板计数低的慢性免疫性血小板减少症。Eltrombopag 可用于心血管的研究。Eltrombopag 对多药耐药的金黄色葡萄球菌 (Staphylococcus aureus) 也有很强的抑制作用。Eltrombopag 还可诱导肝癌细胞凋亡 (apoptosis)。

(E/Z)-Eltrombopag-C 4 is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with C labeled. Z-Eltrombopag is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].

Solid

Thrombopoietin Receptor, Staphylococcus aureus, Apoptosis

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.
[2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.